Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 15.0-55.0,  Infections, Meningococcal Individuals of 15 through 55 years of age on the day of informed consent or assent. 2. Individuals who received Menveo 4 to 6 years prior to enrolment at an age of 11 years or older OR Individuals who received Menactra 4 to 6 years prior to enrolment at an age of 11 years or older OR Individuals who have not received any previous meningococcal vaccine. 3. Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. If the subject is under age 18 at the time of enrolment, the parent(s)/legal guardian(s) of the subject should have voluntarily given written informed consent. 4. Individuals who can comply with study procedures including follow-up. 5. Males Or Females of non-childbearing potential Or Females of childbearing potential who are using an effective birth control method which they intend to use for at least 30 days after the study vaccination  Each subject must not have: 1. History of any meningococcal vaccine administration other than the single vaccination given 4 to 6 years before OR History of any meningococcal vaccine administration. 2. Current or previous, confirmed or suspected disease caused by N. meningitidis. 3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days prior to study vaccination. 4. Progressive, unstable or uncontrolled clinical conditions. 5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. 6. Clinical conditions representing a contraindication to intramuscular vaccination (IM) and blood draws. 7. Abnormal function of the immune system resulting from: 1. Clinical conditions. 2. Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to study vaccination. 3. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination. 8. Received immunoglobulins or any blood products within 180 days prior to informed consent. 9. Received systemic antibiotic treatment within 3 days prior to study vaccination or blood draw. 10. Received an investigational or non-registered medicinal product within 30 days prior to study vaccination. 11. Study personnel as an immediate family or household member. 12. Individuals who have received any other vaccines within 7 days or 14 days prior to vaccination in this study or who are planning to receive any vaccine within 28 days from the study vaccination. 13. Individuals who have experienced a moderate or severe acute infection and/or fever defined as a temperature ≥38°C (100.4°F) within 3 days prior to study vaccination. 14. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study